As the human genome was decoded in the early 21st century, human health and medicine are changing to a new paradigm of precision medicine that seeks active preemptive response through scientific prediction by early diagnosis before the onset of the disease, rather than passive response after the onset of symptoms. In other words, P4 precision medicine, which seeks Predictive, Preventive, Personalized and Participatory medicine, is being sought as the basic concept of healthcare. However, based on the precision analysis technique of innovative genetic marker information, it is integrated with various information technologies such as AI for the industrialization of a huge convergence precision medicine technology.

SYSBIOGEN is developing advanced genetic markers for diseases, accurately diagnosing diseases such as cancer using precision analysis technology and liquid biopsy samples. SYSBIOGEN is also developing an innovative diagnostic system that comprehensively uses multiple indicators such as multiomics and imaging long before the onset of disease symptoms for health life extension in aging society. In particular, SYSBIOGEN is to seek various convergence businesses that enable early prediction of diseases, early safety prevention and evaluation of disease outbreaks, and personalized responses tailored to individual genetic characteristics to prepare for health. In addition, SYSBIOGEN aims at a precision diagnosis and P4 precision medicine-based biotechnology company that will enable future national-level life science researchers and biotechnology business leaders to carry out creative next-generation businesses in all fields, from basic life science research to business development and application.